Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Diagnostic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 227272
This agreement also contains a non-exclusive grant back from Licensee to Licensor.
Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.
Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.
IPSCIO Record ID: 227271
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.
The agreement is exclusive except for the non-exclusive license granted to the U.S. government
Angiogenesis And Tumor Growth In Vivo.
2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth
2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo
Anti-Angiogenesis for the Treatment of Cancer
In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.
IPSCIO Record ID: 227270
– the exclusive worldwide license in the Field of Use to use the Patent to make, use and sell and to have made, have sold and sublicense the Products; and
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any SubLicensee agrees to be bound by the terms and conditions of this Agreement applicable to SubLicensee.
The exclusive license means exclusive except for the non-exclusive license granted to the U.S. government.
Angiogenesis, or the formation of new blood vessels, is necessary for the growth and spread of tumors. Licensee's antibodies and peptides bind to newly exposed sites on proteins, such as collagen, during the remodeling of the extracellular matrix, which occurs during angiogenesis. Objective is to establish our position as a leader in the development and marketing of specific active immunotherapy and other biological products for the treatment and control of cancer.
IPSCIO Record ID: 27678
Diagnostic Field The field of diagnostics, specifically, biomarker analytical assays for human diagnostic, theranostic or prognostic use.
Methods for detecting and modulating the sensitivity of tumor cells.
